Archive - February 2010

• More evidence ARBS are neuroprotective (23/02/2010)
• Placebos not just an inert treatment (23/02/2010)
• Strategies help doctors say 'no' to patients (23/02/2010)
• Early surgery recommended for NVE patients (23/02/2010)
• FDA widens role for statins in US (23/02/2010)
• Warfarin can be stopped 3-6 months post ablation (23/02/2010)
• Insurer defends genetic testing plan (17/02/2010)
• Oestrogen has mixed effect on heart (17/02/2010)
• Statins slightly up diabetes risk (17/02/2010)
• More evidence linking childhood obesity to early death (16/02/2010)
• Patients to choose pathology lab (15/02/2010)
• AUSDRISK identifies asymptomatic high-risk (15/02/2010)
• Lancet retracts controversial MMR paper (10/02/2010)
• Women with gout at greater risk of MI (10/02/2010)
• CHD risk information improves outcomes (10/02/2010)
• Advisory warns of CV risk with androgen therapy (10/02/2010)
• Risk score predicts mortality in Australian cardiac surgery patients (10/02/2010)
• CT best for ruling out CAD (10/02/2010)
• Medicare seeks sense of satisfaction (03/02/2010)
• Doctors call for ban on liver toxic herbal supplement (03/02/2010)
• Pre-op stress testing improves surgery outcomes (03/02/2010)
• Wide variation in antibiotic prophylaxis (03/02/2010)
• Rural Australia needs CVD prevention strategies (03/02/2010)

Back to archive ...